Profile of evolocumab and its cost-effectiveness in patients with high cardiovascular risk: literature review

References

• Roth GA, Huffman MD, Moran AE, et al. Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation. 2015;132(17):1667–1678.
   PubMed Web of Science ®Google Scholar
• Global Cardiovascular RJ. Risk Assessment: strengths and Limitations. High Blood Press Cardiovasc Prev. 2016;23(2):87–90.
   PubMed Web of Science ®Google Scholar
• Zannad F. Cardiovascular high-risk patients – treat to protect, but whom? Medscape J Med. 2008;10(Supp):S2.
   PubMedGoogle Scholar
• Cicero AF, Colletti A, Borghi C. Profile of evolocumab and its potential in the treatment of hyperlipidemia. Drug Des Devel Ther. 2015;9:3073–3082.
   PubMed Web of Science ®Google Scholar
• Repatha SureClick - Summary of Product Characteristics (SPC) - (eMC) [Internet]. [cited 2017 Jul 1]. Available from: https://www.medicines.org.uk/emc/medicine/30628.
   Google Scholar
• Agabiti Rosei E, Salvetti M. Management of hypercholesterolemia, appropriateness of therapeutic approaches and new drugs in patients with high cardiovascular risk. High Blood Press Cardiovasc Prev. 2016;23(3):217–230.
   PubMed Web of Science ®Google Scholar
• Henry CA, Lyon RA, Ling H. Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction. Vasc Health Risk Manag. 2016;12:163–169.
   PubMed Web of Science ®Google Scholar
• Krähenbühl S, Pavik-Mezzour I, von Eckardstein A. Unmet needs in LDL-C lowering: when statins won’t do! Drugs. 2016;76(12):1175–1190.
   PubMed Web of Science ®Google Scholar
• AIM-HIGH Investigators; Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365(24):2255–2267.
   PubMed Web of Science ®Google Scholar
• Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.
   PubMed Web of Science ®Google Scholar
• Kiortsis DN, Giral P, Bruckert E, et al. Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients. J Clin Pharm Ther. 2000;25(6):445–451.
   PubMed Web of Science ®Google Scholar
• Fung V, Sinclair F, Wang H, et al. Patients’ perspectives on nonadherence to statin therapy: a focus-group study. Perm J. 2010;14(1):4–10.
   PubMedGoogle Scholar
• Gupta S. Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders. Vasc Health Risk Manag. 2016;12:421–433.
   PubMed Web of Science ®Google Scholar
• Pfizer discontinues global development of bococizumab, its investigational PCSK9 Inhibitor. Available from: http://www.pfizer.com/news/press-release/press-release-detail/pfizer_discontinues_global_development_of_bococizumab_its_investigational_pcsk9_inhibitor. Last time visited October 9th.
   Google Scholar
• Mikhailidis DP, Wierzbicki AS, Daskalopoulou SS, et al. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr Med Res Opin. 2005;21(6):959–969.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolemia: a randomised, double-blind, placebo controlled trial. Lancet. 2010;375:998–1006.
   PubMed Web of Science ®Google Scholar
• Raal FJ. Lomitapide for homozygous familial hypercholesterolemia. Lancet. 2013;381:7–8.
   PubMed Web of Science ®Google Scholar
• Evolocumab. Aust Prescr. 2016;39(5):180–182.
   PubMed Web of Science ®Google Scholar
• Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154–156.
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Jacobson TA, Preiss D, et al. Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia. Cardiovasc Drugs Ther. 2016;30(3):305–313.
   PubMed Web of Science ®Google Scholar
• Langslet G, Emery M, Wasserman SM. Evolocumab (AMG 145) for primary hypercholesterolemia. Expert Rev Cardiovasc Ther. 2015;13(5):477–488.
   PubMed Web of Science ®Google Scholar
• Foltz IN, Karow M, Wasserman SM. Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know. Circulation. 2013;127(22):2222–2230.
   PubMed Web of Science ®Google Scholar
• Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and, hypercholesterolemic subjects on statins. J Am Coll Cardiol. 2012;60(19):1888–1898.
   PubMed Web of Science ®Google Scholar
• Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366:1108–1118.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolemia, (LAPLACE-TIMI 57): a randomized, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380(9858):2007–2017.
   PubMed Web of Science ®Google Scholar
• Hirayama A, Honarpour N, Yoshida M, et al. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk-primary results from the, phase 3 YUKAWA study. Circ J. 2014;78(5):1073–1082.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Nedergaard BS, Rogers WJ, et al. LAPLACE-2 Investigators. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870–1882.
   PubMed Web of Science ®Google Scholar
• Kiyosue A, Honarpour N, Kurtz C, et al. A phase 3 study of evolocumab (AMG 145) in statin-treated japanese patients at highcardiovascular risk. Am J Cardiol. 2016 1;117(1):40–47.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500–1509.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Dent-Acosta RE, Rosenson RS, et al. GAUSS-3 Investigators. Comparison of PCSK9 inhibitor evolocumab vs ezetimibe in statin-intolerant patients: design of the goal achievement after utilizing an anti-PCSK9 antibody, in statin-intolerant subjects 3 (GAUSS-3) Trial. Clin Cardiol. 2016;39(3):137–144.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316(22):2373–2384.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. FOURIER steering committee and investigators. evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722.
   PubMed Web of Science ®Google Scholar
• Blom DJ, Hala T, Bolognese M, et al. DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370(19):1809–1819.
   PubMed Web of Science ®Google Scholar
• Koren MJ, Lundqvist P, Bolognese M, et al. MENDEL-2 Investigators. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2531–2540.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Stein EA, Dufour R, et al. RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):331–340.
   PubMed Web of Science ®Google Scholar
• Zhang XL, Zhu QQ, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13:123.
   PubMed Web of Science ®Google Scholar
• Gouni-Berthold I, Descamps OS, Fraass U, et al. Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolemia. Br J Clin Pharmacol. 2016;82(6):1412–1443.
   PubMed Web of Science ®Google Scholar
• Markham A. Evolocumab: first global approval. Drugs. 2015;75(13):1567–1573.
   PubMed Web of Science ®Google Scholar
• Fala L. Repatha (Evolocumab): second PCSK9 inhibitor approved by the FDA for patients with familial hypercholesterolemia. Am Health Drug Benefits. 2016;9(SpecFeature):136–139.
   PubMedGoogle Scholar
• Australian Public Assessment Report for Evolocumab (rch). AusPAR. Therapeutic Goods Administration. [Internet]. [cited 2017 Jul 5]. Available from: https://www.tga.gov.au/sites/default/files/auspar-_evolocumab-rch-160503.pdf.
   Google Scholar
• New active substances, subsequent entry biologics, and generic pharmaceuticals. Health Canada New Drug Authorizations: 2015 Highlights. [Internet]. [cited 2017 Jul 10]. Available from: https://www.canada.ca/.
   Google Scholar
• List of Approved Products, FY. 2015. Pharmaceuticals and medical devices agency. (PMDA). [Internet]. [cited 2017 Jul 5]. Available from: https://www.pmda.go.jp/files/000213411.pdf.
   Google Scholar
• Borissov B, Urbich M, Georgieva B, et al. Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years. J Mark Access Health Policy. 2017;5(1):1412753.
   PubMedGoogle Scholar
• Carroll C, Tappenden P, Rafia R, et al. Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia: an evidence review group perspective of a NICE single technology appraisal. PharmacoEconomics. 2017;35(5):537–547.
   PubMed Web of Science ®Google Scholar
• Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA. 2016;316(7):743–753.
   PubMed Web of Science ®Google Scholar
• Korman M, Wisløff T. Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting. Eur Heart J Cardiovasc Pharmacother. 2017 Apr 21. Epub ahead of print. DOI:10.1093/ehjcvp/pvx010
   Web of Science ®Google Scholar
• Villa G, Lothgren M, Kutikova L, et al. Cost-effectiveness of evolocumab in patients with high cardiovascular risk in Spain. Clin Ther. 2017;39(4):771–786.e3.
   PubMed Web of Science ®Google Scholar
• Toth PP, Danese M, Villa G, et al. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. J Med Econ. 2017;20(6):555–564.
   PubMed Web of Science ®Google Scholar
• Gandra SR, Villa G, Fonarow GC, et al. Cost-Effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States. Clin Cardiol. 2016;39(6):313–320.
   PubMed Web of Science ®Google Scholar
• Toth PP, Stevens W, Chou JW. Why published studies of the cost-effectiveness of PCSK-9 inhibitors yielded such markedly different results. J Med Econ. 2017;20(7):749–751.
   PubMed Web of Science ®Google Scholar
• Kawashiri MA, Nohara A, Noguchi T, et al. Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia. The Am J Cardiol. 2012;109(3):364–369.
   PubMed Web of Science ®Google Scholar
• Double-Blind A, Randomized, placebo-controlled, multicenter study assessing the impact of additional LDL-Cholesterol reduction on major cardiovascular events when evolocumab (AMG 145) is used in combination with statin therapy in patients with clinically, evident cardiovascular disease. ClinicalTrials.gov Identifier:NCT01764633. [cited 2017 Aug 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT01764633.
   Google Scholar
• Keating GM. Evolocumab: a review in hyperlipidemia. Am J Cardiovasc Drugs. 2016;16(1):67–78.
   PubMed Web of Science ®Google Scholar
• Krittanawong C, Kitai T, Zhang H, et al. Cardiovascular safety of evolocumab: a systematic review and meta-analysis. Cardiovasc Drugs Ther. 2016;30(6):645–646.
   PubMed Web of Science ®Google Scholar
• McDonagh M, Peterson K, Holzhammer B, et al. A systematic review of PCSK9 inhibitors alirocumab and evolocumab. J Manag Care Spec Pharm. 2016;22(6):641–653q.
   PubMed Web of Science ®Google Scholar